No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AMED240816P85000
- 0.10
- -0.30-75.00%
15min DelayClose Jul 23 10:19 ET
0.10High0.10Low
0.10Open0.40Pre Close18 Volume2.15K Open Interest85.00Strike Price180.00Turnover30.66%IV13.15%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.0321Delta0.0093Gamma977.50Leverage Ratio-0.0108Theta-0.0018Rho-31.37Eff Leverage0.0181Vega
Intraday
- 5D
- Daily
News
Jefferies Upgrades UnitedHealth to Buy, Cites Growth Outlook
Here's Why Amedisys (AMED) Is a Strong Momentum Stock
NASDAQ New 52-Week Highs And Lows
Chewy, Blackrock Fall; Spirit AeroSystems, Amedisys Rise, Monday, 7/1/2024
Amedisys on Track for Largest Percent Increase Since June 2023 -- Data Talk
Amedisys Gains as UnitedHealth to Sell Some Assets to Gain Regulatory Approval
Comments
$Amedisys(AMED.US$ divergency with good fundamental Also gap so it looks good and risk to rewards is acceptable
1
$Inhibikase Therapeutics(IKT.US$
learn from
$Amedisys(AMED.US$
$AMC Entertainment(AMC.US$
$Fulcrum Therapeutics(FULC.US$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
$PharmaCyte Biotech(PMCB.US$
learn from
$Amedisys(AMED.US$
$AMC Entertainment(AMC.US$
$Fulcrum Therapeutics(FULC.US$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
$PharmaCyte Biotech(PMCB.US$
2
Read more
Kofi : Do u see it going above 100 ?